參考文獻(xiàn)

1.中國醫(yī)師協(xié)會皮膚科醫(yī)師分會帶狀皰疹專家共識工作組,國家皮膚與免疫疾病臨床醫(yī)學(xué)研究中心. 中國帶狀皰疹診療專家共識(2022版)[J]. 中華皮膚科雜志,2022,12:1033-1040.

2.中國醫(yī)療保健國際交流促進(jìn)會皮膚科分會. 帶狀皰疹疫苗預(yù)防接種專家共識[J]. 中華醫(yī)學(xué)雜志,2022,102(8):538-543.

3.LU L, SUO L, LI J, et al. A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China [J]. Hum Vaccin Immunother, 2018, 14(11): 2632-5.

4.Steinmann M, L.D., Grosser J, Schmidt J, Hohoff ML, Fischer A, Greiner W, Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and

heterogeneity patterns. Infection, 2024. 52(3): p. 1009-1026.

5.Mu?oz-Quiles C, L.-L.M., Orrico-Sánchez A, Díez-Domingo J, Impact of postherpetic neuralgia: A six year population-based analysis on people aged 50 years or older. J Infect, 2018. 77: p. 131-136.

6.Ghaswalla P, Thompson-Leduc P, Cheng WY, Kunzweiler C, Wang MJ, Bogart M, Patterson BJ, Duh MS, Wojciehowski J, Park S, Yawn BP. Increased Health Care Resource Utilization and Costs Associated with Herpes Zoster Among Patients Aged ≥50 Years with Chronic Obstructive Pulmonary Disease in the United States. Chronic Obstr Pulm Dis. 2021 Oct 28;8(4):502-516.doi: 10.15326/jcopdf.2021.0222. PMID: 34614552; PMCID: PMC8686847.

*騰訊醫(yī)典內(nèi)容團(tuán)隊(duì)出品